Expert opinion: future frontiers and challenges in cancer medicine.

about

Atmospheric pressure plasma jet treatment evokes transient oxidative stress in HaCaT keratinocytes and influences cell physiology.

P2860

Q33459588-CE65FE5F-BC9B-4284-B315-F29FEB6A0596

P2860

Expert opinion: future frontiers and challenges in cancer medicine.

Item

http://www.wikidata.org/entity/Q39612503

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Expert opinion: future frontiers and challenges in cancer medicine.

@en

Expert opinion: future frontiers and challenges in cancer medicine.

@nl

type

Item

label

Expert opinion: future frontiers and challenges in cancer medicine.

@en

Expert opinion: future frontiers and challenges in cancer medicine.

@nl

prefLabel

Expert opinion: future frontiers and challenges in cancer medicine.

@en

Expert opinion: future frontiers and challenges in cancer medicine.

@nl

P1476

Expert opinion: future frontiers and challenges in cancer medicine.

@en

P2093

Mark Lawler

http://www.w3.org/2001/XMLSchema#string

Patrick G Johnston

http://www.w3.org/2001/XMLSchema#string

P2860

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups

Converting a breast cancer microarray signature into a high-throughput diagnostic test.

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia.

How I treat acute promyelocytic leukemia.

The effect of Oncotype DX recurrence score on treatment recommendations for patients with estrogen receptor-positive early stage breast cancer and correlation with estimation of recurrence risk by breast cancer specialists.

P304

e3-5

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1634/THEONCOLOGIST.2012-0210

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

225065844

http://www.w3.org/2001/XMLSchema#string

P698

22639114

http://www.w3.org/2001/XMLSchema#string

P932

3360916

http://www.w3.org/2001/XMLSchema#string

Expert opinion: future frontiers and challenges in cancer medicine.

about

P2860

P2860

Expert opinion: future frontiers and challenges in cancer medicine.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P932